GlobeNewswire

TeraRecon Debuts Next Generation Northstar(TM) AI Explorer at SIIM18

Dela

National Harbor, Maryland - May 31st, 2018, May 31, 2018 (GLOBE NEWSWIRE) -- TeraRecon (www.terarecon.com) today announced that its first-of-kind Northstar(TM) AI Explorer has reached a new milestone that allows physicians to interact with individual measurements, markings, and findings created by AI image processing algorithms. To demonstrate the potential of these AI-assisted workflows, the company is previewing an end-to-end cardiac MR analysis workflow in partnership with EnvoyAI (www.envoyai.com) and Corstem (www.corstem.ai) that provides highly automated results while keeping the physician informed and in control. The new Northstar features are the latest in a rapid progression of technological achievements made as the product evolves from a results viewer to a more powerful and integrated AI interaction and observation portal.

The new Northstar AI Explorer(TM) provides the ability to not only accept or reject certain images and reports created by AI, as Northstar has done previously, but now empowers physicians to fine-tune findings and interrogate the clinical assumptions that underlie the results in AI-generated reports. The system is composed of a web-based user interface that works seamlessly alongside or within the physicians' current PACS, EMR, and enterprise viewing systems.

The Northstar AI Explorer and the EnvoyAI platform together form an application framework upon which any 3rd party algorithm developer can build. "TeraRecon strives to make AI-assisted medical imaging interpretations more accessible to physicians by offering an unprecedented level of transparency into AI functionality along with deep integrations into existing workflows that optimize ease of use and efficiency. By exposing the key clinical assumptions that these AI machines are making and stopping to collect physician feedback before proceeding, we reduce risk while accelerating innovation and clinical adoption", said Jeff Sorenson, President and CEO of TeraRecon.

The cardiac MR analysis workflow prototype is composed of Corstem AI-generated anatomic contours and clinical assumptions being quickly verified or adjusted.  The physician feedback is sent to the Corstem application hosted on the EnvoyAI platform. The workflow then completes the cardiac function and fully quantitative pixel-wise perfusion analyses, marks updated findings in the images, and generates the report. The physician can make further adjustments and send the results to the permanent archive, such as the PACS or VNA.

"The most exciting aspect of the Northstar AI Explorer is that physicians can appreciate the quality of the AI findings", said Pascal Labrecque, Chief Operating Officer of Corstem. Pascal continued, "Our proprietary deep learning algorithm performs cardiac MR contouring with some of the most sophisticated motion correction technology available. The combination of TeraRecon's Northstar AI Explorer and the EnvoyAI platform allows cutting-edge AI technology to really shine."

The trained AI algorithms are not continuously learning from physician feedback in real-time, to ensure that tight version-control and testing regimens are maintained. However, with permission and appropriate data sharing protocols from the healthcare institution, their anonymized image data and physician ground truthing feedback may be shared and used by the algorithm developer to make improved versions.

Northstar was installed at its first beta-release customer site this month, Wake Radiology (www.wakerad.com) in Raleigh, North Carolina. "My expectation is that the Northstar viewer is going to simplify the experience for my radiologists. The output from these AI algorithms are expected to far surpass what we could generate individually on any given day, for specific reports. Volumetric measurements and serial comparisons that could not be done or would take a lot of time to do individually should be automated with AI", said Dr. William Way, Chief Medical Officer of Wake Radiology.  Dr. Way continued, "Having these results readily available and nicely integrated into our PACS and reporting workflows is vastly superior to what we are doing now."

"AI is important to where we are going as a radiology provider, and it is nice to be on the cutting edge", said Matt Dewey, Chief Information Officer of Wake Radiology.  Matt continued, "Because algorithms work differently and each of them has different inputs and outputs, my radiologists would otherwise have to have a different way of working with each one.  Northstar solves this problem by providing a simple and consistent way that our physicians work with the output of algorithms from many sources, and adapting itself to their personal preferences."

TeraRecon AI solutions will be demonstrated during the Society for Imaging Informatics in Medicine annual meeting, May 31st through June 2nd in National Harbor, Maryland at Booth #405. Online demonstrations and more information are available by contacting TeraRecon at info@terarecon.com.

About TeraRecon (www.terarecon.com) TeraRecon is a leader in advanced visualization, image viewing, and post-processing. Our flagship product, iNtuition, consistently leads the advanced visualization category of the industry's leading independent technology analyst. We are committed to redefining advanced visualization by leveraging artificial intelligence, and to improving radiology workflow through personalized automation features that increase efficiency.

About EnvoyAI (www.envoyai.com) EnvoyAI facilitates the streamlined distribution and hospital implementation of trained machine learning algorithms via a vendor-neutral distribution platform. EnvoyAI provides a developer platform, integrations, and an open API for algorithm developers, technology partners, and end users. EnvoyAI assists research institutions and emerging AI companies in the translation and commercialization processes, starting with rapid deployment via a scalable, secure, cloud-based infrastructure with the ability to add local components to facilitate on-site deployments as well. EnvoyAI also works with distribution partners to make algorithms on the platform available to a very wide footprint of hospitals and, ultimately, to physicians. 

About Wake Radiology ( www.wakerad.com Founded in 1953, Wake Radiology is the leading provider of outpatient medical imaging in Central North Carolina. Its physicians have been trained as experts in specific imaging specialties - ranging from breast cancer detection and pediatrics to sports medicine and neuroradiology - to accurately diagnose healthcare issues. Another hallmark of Wake Radiology is its commitment to low-dose imaging and the elimination of unnecessary or duplicate exams. This approach strives to improve patient outcomes and reduces the overall cost of healthcare. Wake Radiology is the region's largest outpatient imaging practice with nearly 50 radiologists who perform close to 600,000 procedures each year. It is the first outpatient imaging provider in the Triangle to earn the American College of Radiology's prestigious Breast Imaging Center of Excellence designation. Wake Radiology is an independent, locally owned and physician-led practice that actively supports the local community.

About CorStem (www.corstem.ai) Corstem is a machine learning and artificial intelligence software developer specialized in medical imaging analysis and computer vision. Founded in 2016, its AI-powered tools are setting the standard in dynamic cardiac analysis. Corstem enables a whole new level of efficiency and automation for diagnosis aid to save valuable physician and patient time. 

IMPORTANT REGULATORY NOTICE: The TeraRecon Northstar and Corstem cardiac MR products mentioned herein are not for clinical use or sale at this time.

Press Inquiries US: 1-650-372-1100 | info@terarecon.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: TeraRecon, Inc via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Oboya signs a cooperation agreement with Gaia regarding biomaterials13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") has signed an important and long-term cooperation agreement on environmentally friendly biomaterials with Gaia Biomaterials AB ("Gaia") in Helsingborg, Sweden. The agreement means that Oboya uses Gaias biomaterials for the production and development of environmentally friendly cultivation products for the cultivation industry. Oboya has been actively involved in innovation, environmental and sustainability issues in recent years, and our goal is to encourage environmental and sustainability in the cultivation industry by offering environmentally friendly cultivation products to our customers. Oboya believes that the use of biomaterials will be important for success in the conversion to a fossil-free cultivation industry worldwide. The cooperation agreement means that Oboya uses Gaias biomaterials in its production and that through Gaias expertise we can develop new environmentally friendly cultivation products. Gaias biomaterials are bi

Oboya tecknar ett samarbetsavtal med Gaia avseende biomaterial13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") har tecknat ett viktigt och långsiktigt samarbetsavtal avseende miljövänligt biomaterial med Gaia Biomaterials AB ("Gaia") i Helsingborg, Sverige. Avtalet innebär att Oboya använder Gaias biomaterial för tillverkning och utveckling av miljövänliga odlingsprodukter till odlingsindustrin. Oboya har under de senaste åren arbetat aktivt med innovation, miljö- och hållbarhetsfrågor och vårt mål är att främja miljö och hållbarhet inom odlingsindustrin genom att erbjuda miljövänliga odlingsprodukter till våra kunder. Oboya anser att användningen av biomaterial kommer att vara viktigt för framgång i omställningen till en fossilfri odlingsindustri världen över. Samarbetsavtalet innebär att Oboya använder Gaias biomaterial i sin produktion och att vi genom Gaias kompetens kan utveckla nya miljövänliga odlingsprodukter. Gaias biomaterial är biologiskt nedbrytbart, komposterbart samt ger upp till 80 % lägre koldioxidutsläpp vid förbränning jämfört

Stillfront: Simutronics reclaims publishing services10.12.2018 14:11Pressmeddelande

PRESS RELEASE December 10, 2018 Simutronics reclaims the publishing services for SIEGE: Titan Wars globally except China Simutronics Corp, a studio within Stillfront Group AB, has ended a co-publishing agreement regarding the mobile game SIEGE: Titan Wars with New York based publishing partner Tilting Point. According to a new agreement, Tilting Point will continue to provide publishing services and market the game in China but Simutronics will run the publishing services and marketing globally from the Group going forward. Simutronics is a leading developer of online roleplaying and mobile games such as DragonRealms, GemStone IV and Lara Croft Relic Run, the latter with more than 23 million downloads. Tilting Point is a new-generation games partner that provides top development studios with expert resources, services, and operational support to optimize high quality live games for success. "I am very pleased to continue the partnership with Tilting Point for the Chinese market as this

Stillfront: Simutronics återtar förläggartjänster10.12.2018 14:11Pressmeddelande

PRESSMEDDELANDE 2018-12-10 Simutronics återtar förläggartjänster för SIEGE: Titan Wars globalt med undantag för Kina Simutronics, en studio inom Stillfront Group, har avslutat ett medförläggaravtal avseende mobilspelet SIEGE: Titan Wars med den New York-baserade förläggarpartnern Tilting Point. Enligt ett nytt avtal kommer Tilting Point fortsatt att tillhandahålla förläggartjänster och marknadsföring av spelet i Kina men på global nivå kommer Simutronics att ansvara för förläggartjänster och marknadsföring av spelet från gruppen. Simutronics är en ledande utvecklare av rollspel och mobila spel som till exempel DragonRealms, GemStone IV och Lara Croft Relic Run, den sistnämnda med mer än 23 miljoner nedladdningar. Tilting Point är den nya generationens spelbolagspartner som förser ledande utvecklingsstudios med expertis, tjänster och operationell support för att optimera högkvalitativa livespel framgångsrikt. "Jag är mycket nöjd över det fortsatta partnerskapet med Tilting Point för den

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum